Etzer Darout
Stock Analyst at BMO Capital
(2.18)
# 2,768
Out of 4,876 analysts
111
Total ratings
36.47%
Success rate
-1.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Outperform | $26 → $15 | $3.82 | +292.67% | 5 | May 13, 2025 | |
| VERV Verve Therapeutics | Maintains: Buy | $18 → $24 | $11.30 | +112.39% | 2 | Apr 15, 2025 | |
| IVA Inventiva | Maintains: Buy | $12 → $9 | $3.05 | +195.08% | 3 | Apr 4, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $82 → $20 | $7.54 | +165.25% | 4 | Mar 12, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $62 → $72 | $55.69 | +29.29% | 2 | Mar 11, 2025 | |
| BNTX BioNTech SE | Maintains: Outperform | $130 → $143 | $106.72 | +34.00% | 4 | Mar 11, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $22 → $3 | $1.45 | +106.90% | 3 | Feb 11, 2025 | |
| IGMS IGM Biosciences | Downgrades: Market Perform | $21 → $2 | $1.08 | +85.19% | 2 | Jan 10, 2025 | |
| EXEL Exelixis | Downgrades: Market Perform | $36 → $40 | $43.67 | -8.40% | 3 | Dec 20, 2024 | |
| TRML Tourmaline Bio | Initiates: Outperform | $50 | $16.54 | +202.30% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $11.64 | +200.69% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $55 | $44.12 | +24.66% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $5.49 | +1,047.54% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.20 | +2,150.00% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $79.68 | +68.17% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 → $34 | $8.14 | +317.69% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $20.50 | +134.15% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $120.01 | -0.01% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $38 | $35.81 | +6.12% | 3 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $25 | $4.70 | +431.91% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $1.19 | +320.17% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.40 | +1,328.57% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $91 | $52.95 | +71.86% | 5 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.04 | +476.92% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3.25 → $3.59 | $2.25 | +59.56% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $69.85 | +17.39% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.84 | +292.56% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $322.83 | -47.34% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $56.19 | -3.90% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $51.07 | -25.59% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $1.47 | +3,437.41% | 1 | Mar 28, 2018 |
Terns Pharmaceuticals
May 13, 2025
Maintains: Outperform
Price Target: $26 → $15
Current: $3.82
Upside: +292.67%
Verve Therapeutics
Apr 15, 2025
Maintains: Buy
Price Target: $18 → $24
Current: $11.30
Upside: +112.39%
Inventiva
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.05
Upside: +195.08%
Arvinas
Mar 12, 2025
Maintains: Outperform
Price Target: $82 → $20
Current: $7.54
Upside: +165.25%
Protagonist Therapeutics
Mar 11, 2025
Reiterates: Outperform
Price Target: $62 → $72
Current: $55.69
Upside: +29.29%
BioNTech SE
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $106.72
Upside: +34.00%
Q32 Bio
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $1.45
Upside: +106.90%
IGM Biosciences
Jan 10, 2025
Downgrades: Market Perform
Price Target: $21 → $2
Current: $1.08
Upside: +85.19%
Exelixis
Dec 20, 2024
Downgrades: Market Perform
Price Target: $36 → $40
Current: $43.67
Upside: -8.40%
Tourmaline Bio
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $16.54
Upside: +202.30%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $11.64
Upside: +200.69%
Dec 6, 2024
Initiates: Market Perform
Price Target: $55
Current: $44.12
Upside: +24.66%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $5.49
Upside: +1,047.54%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.20
Upside: +2,150.00%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $79.68
Upside: +68.17%
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $8.14
Upside: +317.69%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $20.50
Upside: +134.15%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $120.01
Upside: -0.01%
Oct 11, 2024
Maintains: Outperform
Price Target: $34 → $38
Current: $35.81
Upside: +6.12%
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $4.70
Upside: +431.91%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $1.19
Upside: +320.17%
Aug 6, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.40
Upside: +1,328.57%
Jun 4, 2024
Maintains: Outperform
Price Target: $84 → $91
Current: $52.95
Upside: +71.86%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.04
Upside: +476.92%
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $2.25
Upside: +59.56%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $69.85
Upside: +17.39%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.84
Upside: +292.56%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $322.83
Upside: -47.34%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $56.19
Upside: -3.90%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $51.07
Upside: -25.59%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $1.47
Upside: +3,437.41%